Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans
Angarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li C, Esterlis I, Skosnik PD, Radhakrishnan R, Pittman B, Gueorguieva R, Potenza MN, Finnema SJ, Huang Y, Carson RE, Malison RT. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans. Addiction Biology 2021, 27: e13123. PMID: 34852401, PMCID: PMC8891080, DOI: 10.1111/adb.13123.Peer-Reviewed Original ResearchConceptsCocaine use disorderAnterior cingulate cortexRecent cocaine useSynaptic densityMedial orbitofrontal cortexPrefrontal cortexCocaine useOrbitofrontal cortexUse disordersVentromedial prefrontal cortexPositron emission tomography scanPositron emission tomography studyEmission tomography scanSynaptic vesicle glycoprotein 2AHealthy control subjectsVolume of distributionEmission tomography studiesAcute cocaineControl subjectsTomography scanCocaine exposurePreclinical studiesHC subjectsDendritic spinesLifetime cocaine useDetecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory
Kiluk BD, Roos CR, Aslan M, Gueorguieva R, Nich C, Babuscio TA, Carroll KM. Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory. Drug And Alcohol Dependence 2021, 228: 109070. PMID: 34600247, PMCID: PMC8595796, DOI: 10.1016/j.drugalcdep.2021.109070.Peer-Reviewed Original ResearchConceptsAddiction Severity IndexGlobal Severity IndexPsychiatric composite scoreClinical trialsCocaine useCocaine use disorderPsychiatric functioningBrief Symptom InventorySeverity IndexUse disordersASI psychiatric composite scoreSymptom InventoryEffect sizeStart of treatmentComposite scoreClinical trial participantsWeek 12Functional outcomeTreatment periodTrial participantsPsychiatric problemsDrug usePotential functional benefitsMedium effect sizeSubstance users